ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects

First Posted Date
2014-06-04
Last Posted Date
2016-04-12
Lead Sponsor
Allergan
Target Recruit Count
51
Registration Number
NCT02155543

A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas

First Posted Date
2014-05-26
Last Posted Date
2019-06-04
Lead Sponsor
Allergan
Target Recruit Count
432
Registration Number
NCT02147158
Locations
🇺🇸

Watson Investigational Site 108, Las Vegas, Nevada, United States

🇺🇸

Watson Investigational Site 107, Las Vegas, Nevada, United States

🇺🇸

Watson investigational site 142, Pittsburgh, Pennsylvania, United States

and more 54 locations

A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas

First Posted Date
2014-05-26
Last Posted Date
2019-04-30
Lead Sponsor
Allergan
Target Recruit Count
157
Registration Number
NCT02147197
Locations
🇺🇸

Watson Investigational Site 103, Atlanta, Georgia, United States

🇺🇸

Watson Investigational Site 115, Lakewood, Colorado, United States

🇺🇸

Watson Investigational Site 111, Augusta, Georgia, United States

and more 25 locations

A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine

Phase 4
Completed
Conditions
Migraine Disorders
Interventions
Biological: botulinum toxin Type A
First Posted Date
2014-05-26
Last Posted Date
2016-05-27
Lead Sponsor
Allergan
Target Recruit Count
280
Registration Number
NCT02147561

OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity

First Posted Date
2014-05-23
Last Posted Date
2017-04-12
Lead Sponsor
Allergan
Target Recruit Count
53
Registration Number
NCT02145676

Spasticity Registry Evaluating Epidemiology, Treatment Patterns and Clinical Needs

Withdrawn
Conditions
Muscle Spasticity
Interventions
Other: No Intervention
First Posted Date
2014-05-23
Last Posted Date
2015-11-03
Lead Sponsor
Allergan
Registration Number
NCT02145650

Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity

Phase 3
Withdrawn
Conditions
Muscle Spasticity
Stroke
Interventions
Biological: onabotulinumtoxinA
First Posted Date
2014-05-23
Last Posted Date
2014-08-13
Lead Sponsor
Allergan
Registration Number
NCT02145689

Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea

First Posted Date
2014-05-07
Last Posted Date
2019-11-18
Lead Sponsor
Allergan
Target Recruit Count
445
Registration Number
NCT02132117

Retrospective Study of Incidence and Etiology of Reoperation After Primary Augmentation With Natrelle® Breast Implants

First Posted Date
2014-05-07
Last Posted Date
2016-09-13
Lead Sponsor
Allergan
Target Recruit Count
201
Registration Number
NCT02132572

Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

Phase 3
Completed
Conditions
Erythema
Rosacea
Interventions
Drug: Vehicle to AGN-199201
Drug: AGN-199201
First Posted Date
2014-05-06
Last Posted Date
2019-11-18
Lead Sponsor
Allergan
Target Recruit Count
440
Registration Number
NCT02131636
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy